411 related articles for article (PubMed ID: 3258547)
1. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
[TBL] [Abstract][Full Text] [Related]
3. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
4. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
7. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
Fulton RJ; Uhr JW; Vitetta ES
J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
9. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin.
Street NE; Fulton RJ; Sanders VM; Vitetta ES
J Immunol; 1987 Sep; 139(5):1734-8. PubMed ID: 2957434
[TBL] [Abstract][Full Text] [Related]
11. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
13. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
14. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
[TBL] [Abstract][Full Text] [Related]
15. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
17. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
[TBL] [Abstract][Full Text] [Related]
19. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]